Company intelligence / Profile preview

Augnition Labs

Ownership: Private
Development stage: Preclinical

Overview

Augnition Labs is developing innovative AI-driven digital assessment solutions to sensitively detect memory changes. Their technology aims to improve the success of clinical trials in dementia and Alzheimer’s disease by enabling earlier intervention and better patient outcomes. The company is currently focused on product development and validation.

Therapeutic areas: Neurology
Modalities: DeviceDigital therapeuticSoftware as a medical device (SaMD)Artificial intelligence-based assessment tool
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Augnition Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Augnition Labs.

Explore the full profile